Breast Cancer Management
Breast Cancer Management focuses on important aspects of managing the disease by examining top-notch patient-centered clinical research. This information is shared in two ways: as direct clinical findings and in practical formats that are relevant for everyday use in clinics. The journal also emphasizes important breakthroughs in basic and translational research, providing context for future treatment options. Breast Cancer Management serves oncologists and health professionals by delivering the latest insights and perspectives on easing the impact of this common disease. The journal features analyses and reports of recent research and advancements in clinical practice from experts around the globe, all presented in straightforward and easy-to-understand formats. Each article undergoes a thorough review process by at least three independent specialists. The journal invites unsolicited article submissions, and authors must adhere to the journal’s Disclosure & Conflict of Interest Policy, along with major publishing standards such as ICMJE and GPP3.
Outlet metrics
Global
#5939045
United States
#2960968
Health/Medicine
#9849
Articles
-
May 16, 2024 |
futuremedicine.com | Mohamed Kamal |Mohamed Nagy |Omneya Hassanain
The application of personalized medicine in developing countries is a major challenge, especially for those with poor economic status. A critical factor in improving the application of personalized medicine is the efficient allocation of resources. In healthcare systems, optimizing resource allocation without compromising patient care is paramount. This tutorial employs a simulation-based approach to evaluate the efficiency of bed allocation within a hospital setting.
-
May 5, 2024 |
futuremedicine.com | Di Jiang |Abhijat Kitchlu |Launay-Vacher V |Richard T O'Dwyer
RT O'Dwyer has received support for travel and attending meetings from Pfizer and research funding from EMD Serono. DM Jiang has received research funding from Amgen, Tersera, and Astellas Pharma; honoraria from Janssen Oncology, Ipsen, Bayer, EMD Serono, Amgen, and AstraZeneca; consulting fees from Bayer, Pfizer, EMD Serono, McKesson, AstraZeneca, Merck, Janssen Oncology, and Novartis AAA; and support for attending meetings from EMD Serono. A Kitchlu administers funding from Amgen and Janssen.
-
May 2, 2024 |
futuremedicine.com | Laura Durbin |Bhavna Murali |Stephanie Hawthorne |Otávio Clark
Lung cancer is the most common form of cancer in China, with approximately 900,000 new cases diagnosed each year [1]. It is also the deadliest cancer in this country, with approximately 24% of all cancer deaths in China attributed to lung cancer [2].
-
May 2, 2024 |
futuremedicine.com | Emma Guttman-Yassky |Laura Brooks |Ken Clark |Lila Bahadori
This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsWe thank the patients and their caregivers, as well as the study investigators and site staff, for participating in this study. We thank Olivia Fulton for providing feedback on the readability of this publication.
-
Apr 30, 2024 |
futuremedicine.com | Yan Zhang |Bing Luo
Papers of special note have been highlighted as:• of interest; •• of considerable interest• None , Viral causality of human cancer and potential roles of human endogenous retroviruses in the multi-omics era: an evolutionary epidemiology review . ;11:687631. doi: . English. • A total of seven viruses have been found to cause tumors in humans. ;11:687631. doi:. English. • A total of seven viruses have been found to cause tumors in humans.
Breast Cancer Management journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →